Diversion and Injection of Methadone and Buprenorphine Among Clients in Public Opioid Treatment Clinics in New South Wales, Australia

References

• AIHW. (2006). Alcohol and other drug treatment services in Australia 2004–05: Report on the National Minimum Data Set. Drug Treatment Series No. 5. AIHW Cat. No. HSE 43. Canberra: Australian Institute of Health and Welfare.
   Google Scholar
• AIHW. (2007). Alcohol and other drug treatment services in Australia 2005–06: Report on the National Minimum Data Set. Canberra: Australian Institute of Health and Welfare.
   Google Scholar
• Alho, H., Sinclair, D., Vuori, E., Holopainen, A. (2007). Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug and Alcohol Dependence, 88:75–78.
   PubMed Web of Science ®Google Scholar
• Bell, J., Byron, G., Gibson, A., Morris, A. (2004). A pilot study of buprenorphine-naloxone combination tablet (Suboxone®) in treatment of opioid dependence. Drug and Alcohol Review, 23;311–317.
   PubMedGoogle Scholar
• Black, E., Degenhardt, L., Stafford, J. (2006). NSW Drug Trends 2005: Findings from the Illicit Drug Reporting System (IDRS). Sydney: National Drug and Alcohol Research Centre. Technical Report No. 248.
   Google Scholar
• Bruce, R. D., Govindasamy, S., Sylla, L., Kamarulzaman, A., Altice, F. L. (2009). Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market. The American Journal of Drug and Alcohol Abuse, 35:68–72.
   PubMed Web of Science ®Google Scholar
• Darke, S., Ross, J., Hall, W. (1996). Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug and Alcohol Dependence, 43:191–198.
   PubMed Web of Science ®Google Scholar
• Degenhardt, L., Larance, B. K., Bell, J. R., Winstock, A. R., Lintzeris, N., Ali, R. L., Scheuer, N., Mattick, R. P. (2009). Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Medical Journal of Australia, 191:161–165.
   PubMed Web of Science ®Google Scholar
• Fiellin, D. A., O’Connor, P. G. (2002). New federal initiatives to enhance the medical treatment of opioid dependence. Annals of Internal Medicine, 137:688–692.
   PubMedGoogle Scholar
• Gossop, M., Grant, M. (1991). A six country survey of the content and structure of heroin treatment programmes using methadone. British Journal of Addiction, 86:1151–1160.
   PubMedGoogle Scholar
• Humeniuk, R., Ali, R., McGregor, C., Darke, S. (2003). Prevalence and correlates of intraveneous methadone syrup administration in Adelaide, Australia. Addiction, 98:413–418.
   PubMed Web of Science ®Google Scholar
• Jenkinson, R. A., Clark, N. C., Fry, C. L., Dobbin, M. (2005). Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?? Addiction, 100:197–205.
   PubMed Web of Science ®Google Scholar
• Lintzeris, N., Lenne, M., Ritter, A. (1999). Methadone injecting in Australia: a tale of two cities. Addiction, 94:1175–1178.
   PubMed Web of Science ®Google Scholar
• Lintzeris, N., Strang, J., Metrebian, N., Byford, S., Hallam, C., Lee, S., (2006). Methodology for the Randomised Injecting Opioid Treatment Trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK. Harm Reduction Journal, 3:28. doi: 10.1186/1477-7517-3-28.
   PubMedGoogle Scholar
• Madden, A., Lea, T., Bath, N., Winstock, A. R. (2008). Satisfaction guaranteed?? What clients on methadone and buprenorphine think about their treatment. Drug and Alcohol Review, 27:671–678.
   PubMed Web of Science ®Google Scholar
• Mattick, R. P., Digiusto, E., Doran, C. M., OBrien, S., Shanahan, M., Kimber, J., (2001). National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD): Report of results and recommendations. Sydney: National Drug and Alcohol Research Centre.
   Google Scholar
• McCormick, C. G. (2006). Regulatory challenges for new formulations of controlled substances in today's environment. Drug and Alcohol Dependence, 83(Suppl. 1):S63–S67.
   PubMedGoogle Scholar
• Muhleisen, P., Panjari, M., Lee, N. (2003). Buprenorphine dispensing in a cohort of community pharmacies in Victoria. Australian Pharmacist, 22:229–234.
   Google Scholar
• National Drug Strategy. (1998). National policy on methadone treatment. Canberra: Commonwealth Department of Health and Family Services.
   Google Scholar
• Nielsen, S., Dietze, P., Dunlop, A., Muhleisen, P., Lee, N., Taylor, D. (2007). Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. Drug and Alcohol Review, 26:143–151.
   PubMedGoogle Scholar
• NSW Department of Health. (2006). New South Wales Opioid Treatment Program clinical guidelines for methadone and buprenorphine treatment of opioid dependence. Sydney: NSW Department of Health.
   Google Scholar
• NSW Health Department. (2001). NSW policy for the use of buprenorphine in the treatment of opioid dependence: Sydney: NSW Health Department.
   Google Scholar
• Obadia, Y., Perrin, V., Feroni, I., Vlahov, D., Moatti, J. P. (2001). Injecting misuse of buprenorphine among French drug users. Addiction, 96:267–272.
   PubMed Web of Science ®Google Scholar
• Ritter, A., Di Natale, R. (2005). The relationship between take-away methadone policies and methadone diversion. Drug and Alcohol Review, 24:347–352.
   PubMedGoogle Scholar
• Samitca, S., Huissoud, T., Jeannin, A., Dubois-Arber, F. (2007). The role of pharmacies in the care of drug users: what has changed in ten years. European Addiction Research, 13:50–56.
   PubMedGoogle Scholar
• Simoens, S., Matheson, C., Bond, C., Inkster, K., Ludbrook, A. (2005). The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. British Journal of General Practice, 55:139–146.
   PubMed Web of Science ®Google Scholar
• Smith, M. Y., Bailey, J. E., Woody, G. E., Kleber, H. D. (2007). Abuse of buprenorphine in the United States: 2003–2005. Journal of Addictive Diseases, 26:107–111.
   PubMedGoogle Scholar
• Strang, J., Manning, V., Mayet, S., Ridge, G., Best, D., Sheridan, J. (2007). Does prescribing for opiate addiction change after national guidelines?? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England, 1995–2005. Addiction, 102:761–770.
   PubMedGoogle Scholar
• Strang, J., Marsden, J., Cummins, M., Farrell, M., Finch, E., Gossop, M., (2000). Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome. Addiction, 95:1631–1645.
   PubMed Web of Science ®Google Scholar
• Sunjic, S., Howard, J. (1996). “Non-injectables”: methadone syrup and benzodiazepine injection by methadone-maintained clients. Drug and Alcohol Review, 15:245–250.
   PubMedGoogle Scholar
• Treloar, C., Fraser, S., valentine, K. (2007). Valuing methadone takeaway doses: the contribution of service user perspectives to policy and practice. Drugs: Education, Prevention and Policy, 14:61–74.
   Google Scholar
• Verster, A., Buning, E. (2000). European methadone guidelines. Amsterdam: Euro-Methwork.
   Google Scholar
• Victorian Department of Human Services. (2006). Policy for maintenance pharmacotherapy for opioid dependence. Melbourne: Victorian Department of Human Services.
   Google Scholar
• Vidal-Trecan, G., Varescon, I., Nabet, N., Boissonnas, A. (2003). Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug and Alcohol Dependence, 69:175–181.
   PubMed Web of Science ®Google Scholar
• Winstock, A. R., Lea, T., Sheridan, J. (2008). Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. International Journal of Drug Policy, 19:450–458.
   PubMed Web of Science ®Google Scholar